Medicinova (MNOV) vs ProMIS Neurosciences (PMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Medicinova (MNOV) has outperformed ProMIS Neurosciences (PMN) over the past year, gaining 26.2% versus a loss of 35.8%. Over five years, MNOV leads with a -59.7% price change compared with -95.9% for PMN. ProMIS Neurosciences is the larger company by market cap ($82.1 million vs $75.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | PMN |
|---|---|---|
| Share price | $1.54 | $9.15 |
| Market cap | $75.80M | $82.05M |
| 1-day change | -4.35% | +0.33% |
| YTD return | +17.56% | +33.97% |
| 1-year return | +26.23% | -35.79% |
| 5-year return | -59.69% | -95.93% |
| EPS (TTM) | $-0.21 | $-11.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.90 | $27.40 |
| 52-week low | $1.17 | $6.27 |
| Distance from 52-week high | -60.51% | -66.61% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +435.71% | +365.68% |
| Average volume | 322.57K | 84.01K |
| Shares outstanding | 49.22M | 8.97M |
| Employees | 6 | 10 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed PMN by 62.0 percentage points over the past year.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Healthcare · Biotechnology · 6 employees
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Healthcare · Biotechnology · 10 employees
MNOV vs PMN FAQ
Which is bigger, Medicinova or ProMIS Neurosciences?
ProMIS Neurosciences (PMN) is larger, with a market capitalization of $82.05M compared with $75.80M for Medicinova (MNOV).
Which stock has performed better over the past year, MNOV or PMN?
MNOV returned +26.23% over the past 12 months, compared with -35.79% for PMN (price return, excluding dividends). Past performance does not predict future results.
Are Medicinova and ProMIS Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.